BR0212893A - Derivados de 4-pirimidona-3-substituìdo - Google Patents
Derivados de 4-pirimidona-3-substituìdoInfo
- Publication number
- BR0212893A BR0212893A BR0212893-4A BR0212893A BR0212893A BR 0212893 A BR0212893 A BR 0212893A BR 0212893 A BR0212893 A BR 0212893A BR 0212893 A BR0212893 A BR 0212893A
- Authority
- BR
- Brazil
- Prior art keywords
- ring
- substituted
- pyrimidone
- group
- atom
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
"DERIVADOS DE 4-PIRIMIDONA-3-SUBSTITUìDO". Um derivado de pirimidona representado pela fórmula (I) ou seu sal ou seu solvato ou seu hidrato que possui atividade inibitória contra proteína tau de quinase 1: em que R^ 1^ representa um grupo de alkyl C~ 1~-C~ 12~ que pode ser substituído; R representa, por exemplo, um grupo representado pela fórmula (II) a seguir: em que R^ 2^ e R^ 3^ representam independentemente um átomo de hidrogênio ou um grupo de alkyl C~ 1~-C~ 8~; R~ 4~ representa um anel de benzeno que pode ser substituído, um anel de naftaleno que pode ser substituído um anel de indano que pode ser substituído, um anel de tetrahidronaftaleno que pode ser substituído ou um anel heterocíclico opcionalmente substituído que possui de 1 a 4 heteroátomos selecionados a partir do grupo que consiste em átomo de oxigênio, átomo de enxofre e átomo de nitrogênio e que possui de 5 a 10 átomos de constituição de anel no total;
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001331676 | 2001-09-21 | ||
JP2001331678 | 2001-09-21 | ||
JP2001331675 | 2001-09-21 | ||
JP2001331674 | 2001-09-21 | ||
PCT/JP2002/009684 WO2003027080A1 (en) | 2001-09-21 | 2002-09-20 | 3-substituted-4-pyrimidone derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0212893A true BR0212893A (pt) | 2004-08-03 |
Family
ID=27482650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0212893-4A BR0212893A (pt) | 2001-09-21 | 2002-09-20 | Derivados de 4-pirimidona-3-substituìdo |
Country Status (24)
Country | Link |
---|---|
US (1) | US7572793B2 (pt) |
EP (1) | EP1427709B1 (pt) |
JP (1) | JP4368682B2 (pt) |
KR (1) | KR100754596B1 (pt) |
CN (1) | CN1319950C (pt) |
AR (2) | AR043700A1 (pt) |
AT (1) | ATE312827T1 (pt) |
AU (1) | AU2002337498B2 (pt) |
BR (1) | BR0212893A (pt) |
CA (1) | CA2460177C (pt) |
CY (1) | CY1105554T1 (pt) |
DE (1) | DE60208051T2 (pt) |
DK (1) | DK1427709T3 (pt) |
EA (1) | EA007224B1 (pt) |
ES (1) | ES2256540T3 (pt) |
HK (1) | HK1068608A1 (pt) |
HU (1) | HUP0401898A3 (pt) |
IL (2) | IL160701A0 (pt) |
MX (1) | MXPA04002661A (pt) |
NO (1) | NO326694B1 (pt) |
NZ (1) | NZ531637A (pt) |
PL (1) | PL368816A1 (pt) |
TW (1) | TWI303171B (pt) |
WO (1) | WO2003027080A1 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI241298B (en) | 1998-09-25 | 2005-10-11 | Mitsubishi Chem Corp | Pyrimidone derivatives |
AU2002337499B2 (en) | 2001-09-21 | 2007-08-23 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
WO2004055007A1 (en) * | 2002-12-16 | 2004-07-01 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
US7687625B2 (en) | 2003-03-25 | 2010-03-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
CN1867560A (zh) | 2003-08-13 | 2006-11-22 | 武田药品工株式会社 | 4-嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途 |
EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
BRPI0418639B8 (pt) | 2004-03-15 | 2021-05-25 | Takeda Pharmaceutical | compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos |
AR050865A1 (es) * | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
PT1805164E (pt) | 2004-09-29 | 2011-04-11 | Sanofi Aventis | Derivados de 6-(piridinil)-4-pirimidona como inibidores de proteína-cinase tau 1 |
EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
GB0510141D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
TW200740779A (en) * | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
TW200813015A (en) | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
ES2373587T3 (es) * | 2006-08-23 | 2012-02-06 | Pfizer Products Inc. | Compuestos de pirimidona como inhibidores de gsk-3. |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
AR064660A1 (es) | 2006-12-26 | 2009-04-15 | Mitsubishi Tanabe Pharma Corp | Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
KR20100074183A (ko) * | 2007-09-14 | 2010-07-01 | 사노피-아벤티스 | 타우 단백질 키나아제 억제제로서 3-메틸-2-((2s)-2-(4-(3-메틸-1,2,4-옥사다이아졸-5-일)페닐)모폴리노)-6-(피리미딘-4-일)피리미딘-4(3h)-온 |
EP2078717A1 (en) | 2008-01-11 | 2009-07-15 | sanofi-aventis | 6-Pyrimidinyl-pyrimid-2-one derivative |
AR068439A1 (es) * | 2007-09-14 | 2009-11-18 | Mitsubishi Tanabe Pharma Corp | Derivado de 6-pirimidinil-pirimid-2-ona |
AR076014A1 (es) | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
US8940738B2 (en) | 2009-08-13 | 2015-01-27 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone compounds |
JP5535310B2 (ja) * | 2009-08-13 | 2014-07-02 | 田辺三菱製薬株式会社 | タウプロテインキナーゼ1阻害剤としてのピリミドン誘導体 |
WO2011119842A1 (en) | 2010-03-25 | 2011-09-29 | The J. David Gladstone Institutes | Compositions and methods for treating neurological disorders |
US9272055B2 (en) | 2011-04-21 | 2016-03-01 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
RU2621050C2 (ru) * | 2012-01-12 | 2017-05-31 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars) |
BR112015003326A2 (pt) | 2012-08-16 | 2017-07-04 | Ipierian Inc | métodos de tratamento de uma tauopatia |
AU2013334229B2 (en) | 2012-10-25 | 2018-02-15 | Bioverativ Usa Inc. | Anti-complement C1s antibodies and uses thereof |
EP3906944A1 (en) | 2012-11-02 | 2021-11-10 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
PT3007726T (pt) | 2013-06-10 | 2020-06-22 | Ipierian Inc | Métodos de tratamento de uma tauopatia |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US187004A (en) * | 1877-02-06 | Improvement in water-wheels | ||
JPS559099B2 (pt) | 1972-08-07 | 1980-03-07 | ||
JPS4935633A (pt) | 1972-08-09 | 1974-04-02 | ||
JPS5124008B2 (pt) | 1972-08-10 | 1976-07-21 | ||
JPS4935632A (pt) | 1972-08-10 | 1974-04-02 | ||
JPS5271481A (en) | 1975-12-10 | 1977-06-14 | Yoshitomi Pharmaceut Ind Ltd | Synthesis of pyridylpyrimidines |
JPS52139085A (en) | 1976-05-13 | 1977-11-19 | Hokuriku Pharmaceutical | 22allylpiperazine derivative and method for its preparation |
US4507302A (en) | 1979-03-19 | 1985-03-26 | The Upjohn Company | Method for treating arthritis with 6-aryl pyrimidine compounds |
US4619933A (en) | 1979-09-28 | 1986-10-28 | The Upjohn Company | 6-aryl pyrimidines for treating aplastic anemia |
US4725600A (en) | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
DE68916315T2 (de) * | 1988-04-22 | 1994-10-06 | Zeneca Ltd | Pyrimidinon-Derivate. |
DE58908208D1 (de) | 1988-07-29 | 1994-09-22 | Ciba Geigy Ag | Thiouracile als Stabilisatoren für chlorhaltige Polymerisate. |
DE69230148T2 (de) | 1991-12-06 | 2000-05-04 | Max Planck Gesellschaft | Werkzeuge für die Diagnose und Behandlung der Alzheimerschen Krankheit. |
DE4206145A1 (de) | 1992-02-28 | 1993-09-02 | Basf Ag | Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide |
JP3324611B2 (ja) | 1992-07-03 | 2002-09-17 | 三菱化学株式会社 | タウ蛋白質のリン酸化方法 |
JPH06329551A (ja) | 1993-03-22 | 1994-11-29 | Mitsubishi Kasei Corp | アルツハイマー病の予防または治療薬およびそのスクリーニング方法 |
CZ101496A3 (en) | 1993-10-12 | 1996-11-13 | Du Pont Merck Pharma | N-alkyl-n-aryl-pyrimidinamines and derivatives thereof |
EP0948497A2 (en) | 1996-12-05 | 1999-10-13 | Amgen inc. | Substituted pyrimidine compounds and their use |
WO1998024780A2 (en) | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds and their use |
US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
WO1998024782A2 (en) | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
CN1142931C (zh) * | 1997-03-26 | 2004-03-24 | 大正制药株式会社 | 4-四氢吡啶基嘧啶衍生物 |
TWI241298B (en) * | 1998-09-25 | 2005-10-11 | Mitsubishi Chem Corp | Pyrimidone derivatives |
NZ520241A (en) | 2000-02-25 | 2004-05-28 | F | Adenosine receptor modulators |
WO2001070728A1 (en) | 2000-03-23 | 2001-09-27 | Sanofi-Synthelabo | 2-[nitrogen-heterocyclic]pyrimidone derivatives |
EP1136482A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
AU2002337499B2 (en) | 2001-09-21 | 2007-08-23 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
WO2004055007A1 (en) | 2002-12-16 | 2004-07-01 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
-
2002
- 2002-09-20 MX MXPA04002661A patent/MXPA04002661A/es active IP Right Grant
- 2002-09-20 EA EA200400452A patent/EA007224B1/ru not_active IP Right Cessation
- 2002-09-20 DK DK02772870T patent/DK1427709T3/da active
- 2002-09-20 DE DE60208051T patent/DE60208051T2/de not_active Expired - Lifetime
- 2002-09-20 IL IL16070102A patent/IL160701A0/xx unknown
- 2002-09-20 ES ES02772870T patent/ES2256540T3/es not_active Expired - Lifetime
- 2002-09-20 PL PL02368816A patent/PL368816A1/xx not_active Application Discontinuation
- 2002-09-20 AT AT02772870T patent/ATE312827T1/de active
- 2002-09-20 WO PCT/JP2002/009684 patent/WO2003027080A1/en active IP Right Grant
- 2002-09-20 US US10/489,607 patent/US7572793B2/en not_active Expired - Fee Related
- 2002-09-20 CA CA2460177A patent/CA2460177C/en not_active Expired - Fee Related
- 2002-09-20 NZ NZ531637A patent/NZ531637A/en not_active IP Right Cessation
- 2002-09-20 KR KR1020047004113A patent/KR100754596B1/ko not_active IP Right Cessation
- 2002-09-20 BR BR0212893-4A patent/BR0212893A/pt not_active Application Discontinuation
- 2002-09-20 AR ARP020103546A patent/AR043700A1/es unknown
- 2002-09-20 HU HU0401898A patent/HUP0401898A3/hu unknown
- 2002-09-20 TW TW091121652A patent/TWI303171B/zh active
- 2002-09-20 AR ARP020103547A patent/AR036604A1/es active IP Right Grant
- 2002-09-20 AU AU2002337498A patent/AU2002337498B2/en not_active Ceased
- 2002-09-20 JP JP2003530670A patent/JP4368682B2/ja not_active Expired - Lifetime
- 2002-09-20 EP EP02772870A patent/EP1427709B1/en not_active Expired - Lifetime
- 2002-09-20 CN CNB028180178A patent/CN1319950C/zh not_active Expired - Fee Related
-
2004
- 2004-03-03 IL IL160701A patent/IL160701A/en not_active IP Right Cessation
- 2004-04-20 NO NO20041604A patent/NO326694B1/no not_active IP Right Cessation
- 2004-12-07 HK HK04109693A patent/HK1068608A1/xx not_active IP Right Cessation
-
2006
- 2006-03-09 CY CY20061100327T patent/CY1105554T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0212893A (pt) | Derivados de 4-pirimidona-3-substituìdo | |
BR0212892A (pt) | Derivados de 4-pirimidona-3-substituìdo | |
BRPI0615111B8 (pt) | composto, composição farmacêutica, e, uso do composto | |
BR112012016111A2 (pt) | Composto hererocíclico contendo nitrogênio, fungicida agrícola, e, produto intermediário | |
BR0207863A (pt) | Inibidores piridìnicos de metaloproteinases da matriz | |
NO20061793L (no) | 1,4-disubstituerte isoquinilonderlvater som RAF-kinaseinhibitorer nyttige for behandling av proliferative sykdommer | |
TW200716089A (en) | BCRP/ABCG2 inhibitor | |
BR0207209A (pt) | Inibidores de metaloproteinase de matriz de pirimidina | |
BR0109851A (pt) | Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste | |
BRPI0413232A (pt) | novos compostos tendo atividade inibitória contra os trasnportadores dependentes de sódio | |
MA29254B1 (fr) | Derives de pyrazole servant a inhiber les kinases dependantes des cyclines (cdk) et les glycogene synthases kinases (gsk) | |
BRPI0308495B8 (pt) | composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto | |
BRPI0515628A (pt) | composto de 2-morfolina-4-pirimidona | |
EP1854789A4 (en) | CHINAZOLINE DERIVATIVE WITH TYROSINE KINASE HEMMENDER EFFECT | |
BR0316785A (pt) | Derivados de 4-pirimidona-3-substituìdos | |
ATE311367T1 (de) | 5-substituierte alkylaminopyrazol-derivative als pestizide | |
WO2006133928A3 (en) | Use of phenylsemicarbazones for seed treatment | |
BR0113970A (pt) | Compostos de pirimidina e seu uso | |
BRPI0406500A (pt) | processo farmacêutico e compostos preparados pelo mesmo | |
BR0313566A (pt) | Composto de 4-nitroimidazol 1-substituìdo, método para preparar um composto de 4-nitroimidazol, método para preparar um composto de 4-nitroimidazol 1-substituìdo, derivado de 4-nitroimidazol, e, composto | |
ATE414692T1 (de) | Pyridinketone mit herbizideffekt | |
BR0307424A (pt) | Compostos heterocìclicos com atividade inibidora de elastase e seus intermediários | |
BRPI0514077A (pt) | derivados de benzilóxi como inibidores de maob | |
DE60318089D1 (de) | Protein-tyrosine-kinase-inhibitoren | |
BR0116938A (pt) | Derivados de n-aminoimidazol de inibição de hiv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1849 DE 13/06/2006 POR TER SIDO APRESENTADA PAPELETA DE ESCLARECIMENTO. |
|
B25D | Requested change of name of applicant approved |
Owner name: MITSUBISHI PHARMA CORPORATION (JP) , SANOFI-AVENTI Free format text: ALTERADO DE: SANOFI-SYNTHELABO |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |